TCI Wealth Advisors’s Veracyte VCYT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q2
Sell
-198
Closed -$4.42K 2152
2023
Q1
$4.42K Buy
198
+1
+0.5% +$24 ﹤0.01% 1610
2022
Q4
$4.67K Buy
+197
New +$4.58K ﹤0.01% 1574
2022
Q2
Sell
-342
Closed -$9K 2530
2022
Q1
$9K Buy
342
+40
+13% +$1.14K ﹤0.01% 1203
2021
Q4
$12K Sell
302
-3
-1% -$133 ﹤0.01% 1056
2021
Q3
$14K Buy
305
+115
+61% +$5.02K ﹤0.01% 891
2021
Q2
$8K Sell
190
-8
-4% -$342 ﹤0.01% 1150
2021
Q1
$11K Buy
198
+108
+120% +$6.22K ﹤0.01% 830
2020
Q4
$4K Hold
90
﹤0.01% 1024
2020
Q3
$3K Hold
90
﹤0.01% 1021
2020
Q2
$2K Hold
90
﹤0.01% 1142
2020
Q1
$2K Sell
90
-42
-32% -$1.06K ﹤0.01% 1115
2019
Q4
$4K Hold
132
﹤0.01% 960
2019
Q3
$3K Hold
132
﹤0.01% 989
2019
Q2
$4K Buy
132
+42
+47% +$1.05K ﹤0.01% 844
2019
Q1
$2K Buy
90
+32
+55% +$611 ﹤0.01% 1096
2018
Q4
$1K Buy
+58
New +$686 ﹤0.01% 1326

Other funds holding VCYT

TCI Wealth Advisors's VCYT Position: Q2 2023 in Review

TCI Wealth Advisors sold out of Veracyte (VCYT) in Q2 2023, closing a stake of 198 shares — an estimated $4.42K sold.

TCI Wealth Advisors first reported a position in VCYT in Q4 2018 and held it in 16 quarters. The position peaked at $14K in Q3 2021. 232 funds tracked by Wall St. Rank hold VCYT as of Q2 2023.

  • TCI Wealth Advisors reported no remaining Veracyte position as of Q2 2023 after selling out during the quarter.
  • TCI Wealth Advisors sold 198 Veracyte shares in Q2 2023, an estimated $4.42K.
  • TCI Wealth Advisors first reported a position in Veracyte in Q4 2018 and held it in 16 quarters.
  • TCI Wealth Advisors's Veracyte position peaked at $14K in Q3 2021.
  • 232 funds tracked by Wall St. Rank held Veracyte as of Q2 2023.

Based on TCI Wealth Advisors's 13F filing for Q2 2023, filed 4 Aug 2023.